Collaborative study for the establishment of human immunoglobulin BRP replacement batches

Area of Science:

• Pharmaceutical Science
• Immunology
• Biotechnology

Background:

• Human immunoglobulin products are crucial for treating immunodeficiencies and autoimmune diseases.
• Ensuring the quality, functionality, and safety of these products is paramount.
• Specific biological reference preparations (BRPs) are required for quality control testing.

Purpose of the Study:

• To calibrate replacement batches of BRPs for human immunoglobulin quality control.
• To ensure the continuity of quality control testing for Fc function, anticomplementary activity (ACA), and molecular size distribution.
• To establish new Ph. Eur. BRP batches meeting pharmacopoeial standards.

Main Methods:

• A collaborative study involving 17 laboratories (manufacturers and Official Medicines Control Laboratories).
• Calibration of candidate BRP batches against existing human immunoglobulin BRP batches.
• Testing included Fc function, anticomplementary activity (ACA), and molecular size distribution via size-exclusion chromatography.

Main Results:

• Seventeen laboratories successfully calibrated new batches of BRPs.
• Candidate BRPs were adopted by the European Pharmacopoeia (Ph. Eur.) Commission.
• New BRP batches were established for ACA, Fc function, and molecular size testing.

Conclusions:

• The collaborative study successfully established new Ph. Eur. BRPs for human immunoglobulin.
• These new BRPs ensure the continued availability of essential standards for quality control.
• This guarantees the ongoing therapeutic functionality and safety of human immunoglobulin products.